Genprex to Present at Biotech Showcase™ 2020 in San Francisco
January 6, 2020
AUSTIN, Texas & CAMBRIDGE, Mass.— (Jan. 6, 2020) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, nonviral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced it will attend and present at the Biotech Showcase™ 2020 to be held January 13–15, 2020 at the Hilton San Francisco Union Square in San Francisco.
Genprex’s President and Chief Operating Officer, Julien Pham, MD, MPH, will lead the Company’s presentation and, along with Rodney Varner, the Company’s Chief Executive Officer, will be available for one-on-one investor meetings.
Genprex will present at the Biotech Showcase 2020 as follows:
Date: Monday, January 13, 2020
Time: 11:30 a.m. PT (2:30 p.m. ET)
Track: Yosemite C (Ballroom Level)
Location: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry’s largest gatherings and busiest weeks.
“We are delighted that Genprex will be presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform. Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. The company’s lead product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC), has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, please visit the company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.
(877) 774-GNPX (4679)